Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Sales 105

Sales Marketing Prescription Pharma 105

PharmExec

JULY 18, 2023

Pharma giant to serve as Team USA’s partner in prescription medicine and health equity.

Prescription 52

Prescription Medicine Pharma 52

World of DTC Marketing

MARCH 17, 2021

The rapid rollout of Covid-19 vaccines has made household names of Pfizer and AstraZeneca, and the whole industry is winning praise for co-operation” However, the bump in reputation will be short-lived because companies need to earn the public’s trust every day, and pharma is already damaging their perception with people.

Pharma 186

Pharma Competition Prescription Doctors 186

World of DTC Marketing

SEPTEMBER 9, 2021

If pharma is a business, they will find a way to develop, buy, or acquire new drugs. Prescription drug costs are only a small part of healthcare costs, and by 2028 U.S. Prescription drug costs are only a small part of healthcare costs, and by 2028 U.S. healthcare spending will reach $6.2 healthcare.

Healthcare 222

Healthcare Healthcare Government Insurance 222

pharmaphorum

JUNE 27, 2022

The bolt-on deal comes shortly after Ipsen announced plans to sell its consumer health business for around €350 million, leaving it as a pure-play prescription pharma operating in the cancer, rare diseases and neuroscience categories. Ipsen’s CVR offer includes $0.30

Biopharma 87

Biopharma Sales Prescription FDA 87

Clarivate

OCTOBER 25, 2023

While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. With 27.5%

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

PM360

SEPTEMBER 21, 2023

This product would be a more potent prescription version than the OTCs, Casberg notes. The product, manufactured by ARS Pharma and Neurelis Pharma, would be the first needle-free epinephrine alternative to autoinjectors, such as the EpiPen. The impact of the IRA’s price negotiations on payers is mixed, he noted.

Management 105

Management Manufacturing Sales Competition 105